FDA Approves Praluent for Certain Cases of High Cholesterol

Share this content:
FDA Approves Praluent for Certain Cases of High Cholesterol
FDA Approves Praluent for Certain Cases of High Cholesterol

MONDAY, July 27, 2015 (HealthDay News) -- Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who need additional low-density lipoprotein (LDL) cholesterol reduction.

The drug is sanctioned for patients who do not benefit enough from improved diet and the use of statins. Praluent is the first-approved drug in a new class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The drug is an antibody that inhibits the PCSK9 protein, which allows more liver receptors to remove LDL from the blood.

Praluent was evaluated in clinical studies involving 2,476 people with high cholesterol who were at risk of heart attack or stroke, and were taking the highest tolerated dose of a statin. Participants given Praluent saw a reduction in LDL cholesterol ranging from 36 to 59 percent, the FDA said. The most common side effects of Praluent included itching, swelling, pain, or bruising at the injection site, and flu. Serious allergic reactions, some requiring hospitalization, also were reported.

"Praluent provides another treatment option for patients with heterozygous familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough on statins," John Jenkins, M.D., director of the Office of New Drugs in the FDA's Center for Drug Evaluation and Research, said in a statement.

Praluent is marketed by Bridgewater, N.J.-based Sanofi Aventis and Tarrytown, N.Y.-based Regeneron Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »